Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Casopitant morning administration in primary insomnia
NCT00354809Phase 2Completed
- Sponsor
- GSK
- Start
- May 2006
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of casopitant in Insomnia (3 arms), sponsored by GSK. Primary endpoint: Latency to Persistent Sleep at Day 9. Started May 2006; status: completed.
02
Drugs
casopitant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT00354809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00354809.